ase

Appendicitis: Evolving Tools to Diagnose a Classic Disease

Contributing Editor Appendicitis is a common, potentially lethal condition that affects 7% of individuals sometime in their lives. The condition occurs when the appendix, a blind pouch of intestine at the proximal colon, becomes obstructed by mucus, stool, or lymphatic tissue. Infection ensues, which can rapidly evol...

Rapid HIV Testing Increases Possibility of Treatment

According to a November, 2005 joint press release from UNAIDS (Joint United Nations Programme on HIV/AIDS) and the World Health Organization, the number of people living with HIV globally reached an estimated high of 40.3 million people in 2005, with over 3 million deaths caused by AIDS. The latest data from...

Non-Invasive Diagnostic Tests for Celiac Disease

Celiac disease (CD) is an autoimmune inflammatory disease of the small intestine that is triggered in genetically susceptible persons by the ingestion of the gluten-containing grains wheat, rye, barley, and possibly oats. The condition is thought to result from the activation of both a T-cell and B-cell immune respons...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

NEW YORK, July 12, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced results from an open-label Phase III study of ERBITUX(R)(Cetuximab) plus a taxane and carboplatin in the first-linetreatment for metastatic non-small cell lung cancer (NSCLC). Thestudy did not meet its primary endpoint of progression-freesurvival (PFS) as assessed...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposiumof Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation today announced the presentation of findingsfrom the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)study program database showing a statistically significantrelationship between the duration of time spent...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced results of secondary endpoint data from its 99patient, randomized, placebo-controlled, multi-center Phase IIbtrial (DLXLEF-AP4) with...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced positive Phase II data on its leadcompound, PRT054021, an oral Factor Xa inhibitor, today at the XXICongress of the International Society on Thrombosis and Haemostasis(ISTH) in Geneva, Switzerland. The EXPERT trial showed thatPRT054021 was safe, effective, and well tolerated for theprevention of venous th...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

- Results Fail to Demonstrate Meaningful Placebo Adjusted WeightLoss; Obesity Program to be Discontinued NEW YORK, July 09, 2007 /PRNewswire-FirstCall/ -- ManhattanPharmaceuticals, Inc. today announced results of the company's twoPhase 2a clinical trials of oral Oleoyl-estrone (OE). The resultsof both randomized, double-blind, placebo-controlled studies, onein common obesity and the other...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix MedicalCorporation (OTC BB: CONX) and the Company's clinical collaboratorsreported new clinical data demonstrating a significant correlationbetween serum levels of the Company's patented AtherOx(TM)bio-markers and cardiovascular disease. The data was presented atthe XXIst Congress of the International Society on Thrombosis andHemostasis (ISTH...

Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis

- Multinational Phase III Study Meets Primary Endpoint inRheumatoid Arthritis Patients Who Failed to Respond to Anti-tumorNecrosis Factor Treatments - NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche todayannounced that results from the Actemra Radiate (RheumAtoiDArthritIs Study in Anti-TNF FailurEs) trial successfully met itsprimary endpoint in patients with moderate to severe rheumatoi...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.(Nasdaq:AVII) announced today that its partner Cook Medical hascompleted target patient enrollment and released six-monthfollow-up data from a Phase II clinical trial known as Appraisal.The trial, currently being held in Germany, was designed to studythe effect of the Neugene(R) antisense drug Resten-MP(TM), whenused in conj...

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

Animal Study Confirms Caprospinol's (SP-233) Ability to Clear BrainPlaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct CorrelationBetween Removing Beta Amyloid Plaque and Memory Recovery LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is ple...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 10, 2007 - BusinessWeekpublished an article on July 6 discussing the race bypharmaceutical and biotechnology companies to be first to bring tomarket an effective angiogenesis treatment for cardiovasculardisease. While angiogenesis therapies are being pursued bySanofi-Aventis, Boston Scientific, Baxter, and Genzyme, amongothers, the article highlights a...

NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc.(NASDAQ: NEXM), a developer of innovative transdermal treatmentsbased on the NexACT(R) drug delivery technology, today announcedthat Novartis Pharma AG has completed patient enrollment for PhaseIII clinical trials for NM100060, a topical treatment foronychomycosis (nail fungus). Pursuant to the terms of the licensingagreement w...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa ClinicalTrial Results First clinical Results Confirm Potential New Application of KeyProduct in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced the positiveclinical results of its...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma MedicalLtd., a specialty pharmaceutical company focused on the developmentand commercialization of drug products utilizing a proprietaryactive transdermal drug delivery technology, announced todaypromising results of its phase I clinical trials demonstrating thesafety and pharmacokinetic profile of its ViaDerm-hPTH (1-34)product for th...

Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announces that positive interim datafrom an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat advanced sarcoma patients was presented at theEuropean Society of Medical Oncology (ESMO) meeting held July 5-8,2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/IIStudy of...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

CAMBRIDGE, Mass., July 06, 2007 /PRNewswire-FirstCall/ --Genzyme Corp. announced top-line data today from the first of twoPhase 3 clinical studies to assess the safety and efficacy oftolevamer liquid, an investigational, non-antibiotic, polymertherapy for patients with Clostridium difficile associated diarrhea(CDAD). The second Phase 3 study of tolevamer liquid is fullyenrolled and resul...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

BRIDGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Results fromthe primary analysis of a randomized, controlled, open-label, Phase3 study showed that 77 percent of treatment-experienced HIV-1infected adults taking PREZISTA(TM) (darunavir) 600 mg tablets with100 mg ritonavir (PREZISTA/r) twice daily, plus an optimizedbackground regimen (OBR) of antiretroviral (ARV) agents, reached aplasma v...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 6, 2007 - BusinessWeek todaypublished an article discussing the race by pharmaceutical andbiotechnology companies to be first to bring to market an effectiveangiogenesis treatment for cardiovascular disease. Whileangiogenesis therapies are being pursued by Sanofi-Aventis, BostonScientific, Baxter, and Genzyme, among others, the articlehighlights a very...

Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea

LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA(SWX:COPN) announced today positive preliminary results from itsphase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ininfectious diarrhoea. CB-01-11 is a broad spectrum, semi-syntheticantibiotic that is not absorbed when taken in tablet form. Throughthe use of Cosmo's MMX(tm) technology, wh...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood canpotentially improve the quality of life for patients whose lowerextremities are affected by peripheral vascular disease, accordingto a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- BeikeBiotechnology Co., Ltd. (<a target="_blank" href="http://www.beikebiotech.com/">http://www.beikebiotech.com )today announced tha...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)

GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positiveinterim results from the ongoing Phase I study of its leaddevelopment programme, ALX-0081, an anti-thrombotic treatment.ALX-0081 is a novel ´first-in-class´ therapeuticNanobody® targeting von Willebrand Factor (vWF), which canreduce the risk of thrombosis in patients with acute coronarysyndrome. The Pha...

Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee

- Pain Reductions Observed at Eight Weeks Sustained up to 12 Weeksand Drug Remains Very Well Tolerated - SOUTH SAN FRANCISCO, Calif., July 02, 2007/PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminarylonger-term, follow-up results from a Phase 2 study showing that a1mg treatment with Adlea(TM) (formerly 4975) in patients withmoderate-to-severe osteoarthritis of the knee prod...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced today that it will present clinicaland preclinical data on its oral Factor Xa inhibitor and on itsintravenous and oral ADP receptor antagonist at the XXI Congress ofthe International Society of Thrombosis and Haemostasis (ISTH) inGeneva, Switzerland on July 6 through July 12, 2007. The EXPERT...

Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial

Provides Update to Timeline for Second Pivotal Phase 3 Trial CL-05 CHICAGO, July 02, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced the confirmation ofsupplemental efficacy data from Trial CL-06, the first of twopivotal Phase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatme...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM)Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today reported that new data werepresented on the comparative Phase III clinical trial evaluating aVELCADE based therapy in newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem...

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

LONDON, 2 July2007: Chi-Med, the Hutchison Whampoa backed pharmaceutical andhealthcare Group, today announces positive results for its Phase IIproof-of-concept study...